バイオバンクの世界市場：製品タイプ別、バイオ標本タイプ別、バイオバンクタイプ別、サービス別、用途別、地域範囲別および予測

バイオバンクの市場規模と予測

バイオバンク市場規模は2024年に711億4,000万米ドルと評価され、2026～2032年にかけてCAGR 5.50%で成長し、2032年には1,091億8,000万米ドルに達すると予測されます。

バイオバンクは、生物学的サンプルや遺伝子情報、健康記録などの関連データを保存し、研究への応用に役立てるものです。

バイオバンクは、研究者が様々な集団から収集された、膨大で十分に特性化されたサンプルコレクションにアクセスできるようにすることで、生物医療研究において重要な役割を果たしています。バイオバンクは、病気に対する遺伝的素因を調べたり、個別化医療の治療法を開発したり、人間の健康に対する環境の影響を調査したりするのに利用できます。

将来のバイオバンクは、より良いデータ管理と分析のために人工知能やブロックチェーンなどの最新技術を取り入れることで、その展望を広げていくことが期待されています。この変化により、研究セグメントの枠を超えたより大きなパートナーシップが可能になり、バイオマーカーの発見が加速し、オーダーメイドの医薬品開発が支援され、最終的には精密医療とヘルスケアイノベーションの未来が変わることになります。

世界のバイオバンク市場力学

世界のバイオバンク市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

個別化医療に対する需要の高まり：個別化医療に対する需要の高まり：個別化医療に対する需要は過去10年間で徐々に高まっています。正確な数字は分からないが、多数の医療団体や研究機関がこのセグメントへの関心の高まりを指摘しています。精密医療市場は大きく拡大すると予想されており、2020～2025年にかけてのCAGRは10～12％という予測もあります。

バイオマーカー調査への注目の高まり：バイオマーカー研究は近年著しい進歩を遂げています。世界のバイオマーカー市場は上昇しており、2019～2024年のCAGRを13-15%と予測する予測もあります。この拡大の背景には、製薬・バイオテクノロジー産業における研究開発費の増加、がん罹患率の上昇、診断技術の進歩などがあります。

生物医療研究と医薬品開発の成長：バイオバンクは、製薬企業やバイオテクノロジー企業が薬の発見や開発手順を加速するのに役立っています。研究者は広範な生物学的情報を利用して新薬の標的を特定し、治療法のアイデアを検証し、臨床検査デザインを最適化することで、新薬の上市にかかる時間とコストを削減することができます。

技術の進歩：サンプルの収集、保管、管理における技術の進歩は、バイオバンクの効率性と拡大性を劇的に改善しました。自動化、ロボット、クラウドベースの技術により、バイオバンクはサンプルをより効率的に保管・回収し、長期にわたってサンプルの完全性を維持し、世界中の研究機関でシームレスなデータ共有をサポートできるようになりました。

主要課題

倫理的・法的考察：バイオバンクは、許可、プライバシー、データ保護に関する困難な倫理的・法的枠組みを乗り越えなければならないです。透明性とドナーの権利を維持しながら、複数の管轄区域にまたがる規則へのコンプライアンスを確保することは、大きな問題となります。

持続可能性と資金：バイオバンクは、インフラを維持し、サンプルを保管し、データを管理するために多大な財源を必要とします。公的バイオバンクも民間バイオバンクも、予算制限を守りながら長期的な資金を確保し、長期的な持続可能性を保証する上で継続的な問題を抱えています。

サンプルの質と標準化：サンプルの完全性の維持、均一な収集技術の保証、分析前のばらつきの低減は、すべてバイオバンクにおける重要な問題です。サンプルの取り扱い、保管条件、メタデータの記録におけるばらつきは、研究の再現性と研究結果の信頼性に影響を与える可能性があります。

データの統合と互換性：バイオバンクから様々な生物学的、臨床的、ゲノムデータを統合するには、データ標準、他のシステムとの互換性、データセキュリティなどの技術的な問題があります。研究協力や臨床応用においてバイオバンクのリソースを最大限に活用するためには、データ形式の調和と効果的なデータ共有の枠組みの構築が不可欠です。

主要動向

疾患特定バイオバンクの拡大：がん、心血管疾患、珍しい遺伝子異常など、特定の疾患や病態に特化したバイオバンクを構築する傾向が強まっています。このような特化型バイオバンクは、特定の疾患を持つ個人のサンプルやデータを収集し、より焦点を絞った研究や個別化された治療開発を可能にします。

ビッグデータとAIの統合：バイオバンクでは、膨大なデータセットから貴重な知見を引き出すために、ビッグデータ分析と人工知能（AI）の利用が進んでいます。AIアルゴリズムは、多数の情報源からの広範な生物学的・臨床的データを用いて、バイオマーカーの同定、疾患の進行予測、治療戦略の最適化を支援します。

世界のコラボレーションとデータ共有の取り組み：バイオバンク、研究機関、製薬企業は世界規模で協力しています。データ共有、手順の標準化、倫理規範の調和を促進する取り組みにより、さまざまなサンプルセットへのアクセスが可能になり、越境科学的発見が加速されます。

バーチャルバイオバンクとデジタルツインの台頭：デジタルモデルが本物の生物学的サンプルやデータの特性を模倣するバーチャルバイオバンクが人気を集めています。こうしたデジタルツインによって、研究者は実際のサンプルを必要とせずに、仮想的な検査を実施し、研究計画を強化し、結果を予測することができるようになり、コストを削減し、研究効率を高めることができます。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主要調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 バイオバンク市場：製品別

• 検査情報管理システム（LIMS）
• バイオバンク機器

第5章 バイオバンク市場：バイオ標本タイプ別

• 臓器
• 幹細胞

第6章 バイオバンク市場、バイオバンクタイプ別

• リアル
• バーチャル

第7章 バイオバンク市場：サービス別

• バイオバンク＆リポジトリ
• ラボ処理
• クオリフィケーション/バリデーション
• コールドチェーンロジスティクス

第8章 バイオバンク市場：用途別

• 治療
• 創薬・臨床研究
• 臨床診断

第9章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第10章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第11章 競合情勢

• 主要企業
• 市場シェア分析

第12章 企業プロファイル

• Thermo Fisher Scientific
• Merck KGaA
• QIAGEN
• Hamilton Company
• Avantor
• Tecan
• BD（Becton, Dickinson and Company）
• Promega Corporation
• Brooks Automation
• Biovault Family

第13章 市場展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第14章 付録

• 略語リスト
• 供給源と参考文献

Biobanks Market Size and Forecast

Biobanks Market size was valued at USD 71.14 Billion in 2024 and is projected to reach USD 109.18 Billion by 2032, growing at a CAGR of 5.50% from 2026 to 2032.

Biobanks help store biological samples and associated data, such as genetic information and health records, for further application in research.

They play an important role in biomedical research by giving researchers access to vast, well-characterized sample collections from a variety of populations. Biobanks can be used to examine genetic predispositions to diseases, develop personalized medicine treatments, and investigate environmental influences on human health.

In the future, biobanks are expected to broaden their scope by incorporating modern technologies such as artificial intelligence and blockchain for better data administration and analysis. This change will enable greater partnerships across research disciplines, speed biomarker discovery, and aid in the development of tailored medicines, ultimately changing the future of precision medicine and healthcare innovation.

Global Biobanks Market Dynamics

The key market dynamics that are shaping the global biobanks market include:

Key Market Drivers:

Rising Demand for Personalized Medicine: The demand for individualized medication has been gradually increasing during the last decade. While I do not have exact figures, numerous health groups and research institutions have indicated increased interest in this sector. The precision medicine market is expected to expand significantly, with some projections indicating a compound annual growth rate (CAGR) of 10-12% between 2020 and 2025.

Increasing Focus on Biomarker Research: Biomarker research is witnessing significant progress in recent years. The global biomarkers market is rising, with some forecasts predicting a CAGR of 13-15% from 2019 to 2024. This expansion is being driven by causes such as increase in R&D spending in the pharmaceutical and biotechnology industries, rising cancer rates, and advances in diagnostic technologies.

Growth in Biomedical Research and Drug Development: Biobanks help pharmaceutical and biotechnology businesses accelerate medication discovery and development procedures. Researchers can use extensive biological information to identify new drug targets, validate therapeutic ideas, and optimize clinical trial designs, lowering the time and costs associated with bringing new medicines to market.

Technological Advancement: Technological advancements in sample collection, storage, and management have dramatically improved biobank efficiency and scalability. Automation, robots, and cloud-based technologies allow biobanks to store and retrieve samples more efficiently, maintain sample integrity over time, and support seamless data sharing across research institutions around the world.

Key Challenges:

Ethical and Legal Considerations: Biobanks must navigate difficult ethical and legal frameworks related to permission, privacy, and data protection. Ensuring compliance with rules across several jurisdictions while retaining transparency and donor rights presents substantial problems.

Sustainability and Funding: Biobanks require significant financial resources to maintain infrastructure, store samples, and manage data. Both public and private biobanks have continual issues in securing long-term funding while adhering to budget limits and guaranteeing long-term sustainability.

Sample Quality and Standardization: Maintaining sample integrity, assuring uniform collection techniques, and reducing pre-analytical variability are all key problems in biobanking. Variations in sample handling, storage conditions, and metadata recording can have an impact on research reproducibility and the reliability of study results.

Data Integration and Compatibility: Integrating varied biological, clinical, and genomic data from biobanks presents technical issues such as data standards, compatibility with other systems, and data security. Harmonizing data formats and building effective data sharing frameworks are critical for making the most of biobank resources in research collaborations and clinical applications.

Key Trends:

Expansion of Disease-certain Biobanks: There is an increasing trend of creating biobanks dedicated to certain diseases or conditions, such as cancer, cardiovascular disease, and uncommon genetic abnormalities. These specialized biobanks collect samples and data from individuals with specific illnesses, allowing for more focused research and individualized treatment development.

Integration of Big Data and AI: Biobanks are increasingly using big data analytics and artificial intelligence (AI) to extract valuable insights from massive datasets. AI algorithms aid in the identification of biomarkers, disease progression prediction, and treatment strategy optimization using extensive biological and clinical data from numerous sources.

Global Collaboration and Data Sharing Initiatives: Biobanks, research institutes, and pharmaceutical corporations are working together on a global scale. Initiatives that promote data sharing, procedure standardization, and ethical norms harmonization enable greater access to different sample sets and accelerate scientific discoveries across borders.

The Rise of Virtual Biobanks and Digital Twins: Virtual biobanks, in which digital models mimic the properties of genuine biological samples and data, are gaining popularity. These digital twins allow researchers to run virtual tests, enhance study designs, and forecast outcomes without requiring actual samples, lowering costs and increasing research efficiency.

Global Biobanks Market Regional Analysis

Here is a more detailed regional analysis of the global biobanks market:

North America:

North America is anticipated to hold major share in the global biobanks market over the forecast period.

North America has a solid foundation in research and development, with major government and commercial funding supporting biobank activities.

The region has a well-established healthcare infrastructure and a high prevalence of chronic diseases, which increases demand for biospecimens in research to improve diagnosis and treatment.

Furthermore, an increasing emphasis on personalized and precision medicine increases the demand for biobanks in North America. This convergence of circumstances establishes North America as the clear worldwide biobanks industry leader.

Asia Pacific:

In terms of global biobanks market growth, the Asia Pacific region is unquestionably the leader. This rapid increase can be due to a variety of things.

Governments in China, Japan, and South Korea are increasing their investments in R&D. Second, the rising frequency of chronic diseases, combined with a developing healthcare infrastructure, increases the demand for biospecimens utilized in research to improve diagnoses and treatments.

Increasing awareness of the use of biobanks in personalized treatment is moving the market forward. This convergence of circumstances is enabling the Asia Pacific region exhibit fastest growth in the biobank market.

Global Biobanks Market: Segmentation Analysis

The Global Biobanks Market is segmented on the basis of By Product, By Bio Specimen Type, By Biobank Type, By Service and By Application, By Geography.

Biobanks Market, By Product

• Laboratory Information Management System (LIMS)
• Biobanking Equipment

Based on Product, the Global Biobanks Market is segmented into LIMS and Biobanking Equipment. Biobanking Equipment is the largest segment of the global biobanks market, since it includes key tools for sample collection, storage, and preservation. LIMS (Laboratory Information Management Systems) is the fastest-growing market, driven by the increased demand for effective data management, sample tracking, and the incorporation of modern digital technologies into biobanking processes.

Biobanks Market, By Bio Specimen Type

• Organs
• Stem Cells

Based on Bio specimen Type, the Global Biobanks Market is segmented into Organs and Stem Cells. Organs are the most common bio specimen type in the worldwide biobanks market, owing to their vital role in transplant research and other scientific investigations. Stem cells are the fastest-growing segment, owing to their enormous potential in regenerative medicine, disease modeling, and tailored treatment strategies.

Biobanks Market, By Biobank Type

• Real
• Virtual

Based on Biobank Type, the Global Biobanks Market is segmented into Real and Virtual. Real biobanks are the most common form in the global biobanks market, as they were originally established for the physical collection, storage, and management of biological samples. Virtual biobanks are the fastest-growing segment, spurred by advances in digital technologies and rising demand for remote access to biological data for research reasons.

Biobanks Market, By Service

• Biobanking & Repository
• Lab Processing
• Qualification/Validation
• Cold Chain Logistics

Based on Service, the Global Biobanks Market is segmented into Biobanking & Repository, Lab Processing, Qualification/Validation, and Cold Chain Logistics. Biobanking & Repository is the dominating service sector in the global biobanks market, as it is biobanks' primary duty to collect, store, and manage biological samples. Cold Chain Logistics is the fastest-growing market, driven by the growing need to preserve biological samples' integrity throughout transportation and storage under strict temperature control settings.

Biobanks Market, By Application

• Therapeutics
• Drug Discovery & Clinical Research
• Clinical Diagnostics

Based on Application, the Global Biobanks Market is segmented into Therapeutics, Drug Discovery & Clinical Research, and Clinical Diagnostics. Drug Discovery & Clinical Research dominates the worldwide biobanks market, owing to the widespread usage of biobanked samples in the development of novel medications and clinical trials. Clinical Diagnostics is the fastest-growing market, driven by rising demand for precision medicine and the use of biobanks to uncover illness biomarkers and create diagnostic tests.

Biobanks Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Biobanks Market are classified into North America, Europe, Asia Pacific, and Rest of the World. North America dominates the global biobanks market, owing to advanced healthcare infrastructure, significant research funding, and a large number of established biobanks. Asia Pacific is the fastest-growing area, driven by increased healthcare spending, increased awareness of customized treatment, and the expansion of biobank projects.

Key Players

The "Global Biobanks Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific, Merck KGaA, QIAGEN, Hamilton Company, Avantor, BD (Becton, Dickinson and Company), Promega Corporation, Brooks Automation, Biovault Family.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Biobanks Market: Recent Developments
• In September 2023, Sheikh Khaled bin Mohamed, Abu Dhabi's Crown Prince, has approved plans to use human stem cells and tissues to conduct personalized medical research. He approved the plan during a meeting of the Abu Dhabi Executive Council. Members of Abu Dhabi's Department of Health presented the plans to Sheikh Khaled. According to the Abu Dhabi Media Office, the initiative would establish a biobank to enable the provision of personalised medicine through innovative treatment programmes that use human stem cells and tissues to conduct medical research.
• In Jun 2022, Mars Petcare today unveiled an unparalleled scientific endeavor aimed at improving understanding of pet health and disease, as well as assisting scientists and veterinarians in developing personalized pet care. The MARS PETCARE BIOBANKTM intends to be the largest and most comprehensive real-world study of its type, collecting 20,000 pets (10,000 dogs and 10,000 cats) from across the United States over a ten-year period.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Biobanks Market, By Product

• Laboratory Information Management System (LIMS)
• Biobanking Equipment

5. Biobanks Market, By Bio Specimen Type

• Organs
• Stem Cells

6. Biobanks Market, By Biobank Type

• Real
• Virtual

7. Biobanks Market, By Service

• Biobanking & Repository
• Lab Processing
• Qualification/Validation
• Cold Chain Logistics

8. Biobanks Market, By Application

• Therapeutics
• Drug Discovery & Clinical Research
• Clinical Diagnostics

9. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

10. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

11. Competitive Landscape

• Key Players
• Market Share Analysis

12. Company Profiles

• Thermo Fisher Scientific
• Merck KGaA
• QIAGEN
• Hamilton Company
• Avantor
• Tecan
• BD (Becton, Dickinson and Company)
• Promega Corporation
• Brooks Automation
• Biovault Family

13. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

14. Appendix

• List of Abbreviations
• Sources and References